Search Site

Charles G. Drake, MD, PhD

  • Professor of Medicine
  • Co-Director, Cancer Immunotherapy Programs
Charles G. Drake, MD, PhD

Dr. Charles G. Drake has joined NewYork-Presbyterian/Columbia University Medical Center (CUMC) as director of genitourinary oncology and associate director for clinical research at the Herbert Irving Comprehensive Cancer Center. A nationally recognized expert in immunotherapy, Professor Drake will also serve as co-director of Columbia’s Cancer Immunotherapy Programs and on the faculty of CUMC.

“Charles is one of the top minds in immunotherapy and in prostate cancer research and therapies,” said Dr. Gary Schwartz, chief of the Division of Hematology/Oncology at NewYork-Presbyterian/Columbia University Medical Center, associate director for clinical research at the Herbert Irving Comprehensive Cancer Center, and Clyde ’56 and Helen Wu Professor of Oncology (in Medicine). “By bringing him on, NewYork-Presbyterian/Columbia is establishing itself as an emerging powerhouse in immunotherapy, which will allow us to unlock the mysteries of our immune system so we can bring new hope to patients with prostate and other genitourinary malignancies.”

Dr. Drake is a physician-scientist with a Ph.D. in immunology, whose work focuses on understanding and fighting advanced-stage cancers with the immune system. He is known for rapidly incorporating discoveries made in the research lab into innovative clinical trials, including anti-tumor vaccines. His most recent work has focused on the body’s immunological response to radiation therapy and how immunotherapy and radiation therapy can be used in concert to treat cancer. 

“Immunotherapy represents a new frontier in prostate cancer. We’re also looking at how it can be used synergistically with traditional therapies, both in prostate cancer as well as in other tumor types,” said Dr. Drake. “It is truly an honor to join NewYork-Presbyterian/Columbia, which has shown a deep commitment to building a world-class clinical and translational program in immunology across the spectrum of cancers.”

Prior to joining NewYork-Presbyterian/Columbia, Dr. Drake served as the co-director of the Cancer Immunology Program at Johns Hopkins Kimmel Cancer Center. He is also a professor of oncology, urology, and immunology. As co-director of the Prostate Cancer Multi-Disciplinary Clinic, he developed a novel transgenic model of prostate cancer, in which a unique antigen is expressed exclusively in the prostate gland and in prostate tumors. Earlier in his Hopkins career, he was an associate professor in the Department of Oncology and an assistant professor of medical oncology at the institution’s Kimmel Cancer Center. Dr. Drake was active in teaching, leading a small group in the medical school immunology course for many years. His research has been published in prestigious journals such as the New England Journal of Medicine, Cancer Research, the Journal of Clinical Investigation, and the Journal of Clinical Oncology.

Dr. Drake received both his bachelor’s degree in electrical engineering and his master’s degree in biomedical engineering from Rutgers University. He completed a Ph.D. program at the National Jewish Center for Immunology and Respiratory Medicine at the University of Colorado Health Sciences Center, and later earned his M.D. from the University of Colorado as part of the MSTP program. He did his internship and residency in internal medicine at the Osler Medical Service of Johns Hopkins Hospital, and did his medical oncology fellowship training in the Johns Hopkins Department of Oncology.

Departments and Divisions

  • Department of Medicine
    Division of Hematology/Oncology

Areas of Expertise

  • Testicular Cancer
  • Prostate Cancer
  • Kidney & Adrenal Cancer
  • Bladder Cancer
  • Medical Oncology
  • Internal Medicine
  • Clinical Research Trials
  • Immunology
  • Genitourinary Cancer

Education & Training

  • MD, PhD, University of Colorado Health Sciences Center
  • Internship: Johns Hopkins Hospital
  • Residency: Johns Hopkins Hospital
  • Fellowship: Johns Hopkins Hospital

Locations

  • CUMC/Herbert Irving Pavilion

    161 Fort Washington Avenue
    Floor: 9
    New York, NY 10032
    For new and current patient appointments, call:
    (212) 305-5098

Centers / Institutes / Programs

  • Herbert Irving Comprehensive Cancer Center

Provider Affiliations

  • NewYork-Presbyterian/Columbia

Insurance Programs

Please contact the provider's office directly to verify that your particular insurance is accepted.

  • Aetna [EPO, HMO, Medicare Managed Care, NY Signature, POS, PPO, Signature Administrators, Student Health]
  • Affinity [Access (Exchange), Essential Plan, Medicaid Managed Care, Medicare Managed Care]
  • Amida Care [Special Needs Plan]
  • Cigna [EPO, Great West, HMO, POS, PPO]
  • Emblem/GHI [HMO, Medicare Managed Care, PPO]
  • Emblem/HIP [ConnectiCare, EPO, Essential Plan, HMO, Medicaid Managed Care, Medicare Managed Care, POS, PPO, Select Care (Exchange), Vytra]
  • Empire Blue Cross Blue Shield [Blue Priority, EPO, HMO, Medicare (Mediblue), NYP Employee Plan, Pathway (Exchange), POS, PPO]
  • Empire Blue Cross Blue Shield HealthPlus [Child/Family Health Plus, Essential Plan, Medicaid Managed Care]
  • Fidelis Care [Child/Family Health Plus, Medicaid Managed Care, Medicare Managed Care]
  • Healthfirst [Child/Family Health Plus, Medicaid Managed Care, Medicare Managed Care]
  • Local 1199 [Local 1199]
  • MagnaCare [MagnaCare]
  • Multiplan [Multiplan]
  • Oxford Health Plans [Freedom, Liberty, Medicare Managed Care]
  • POMCO [POMCO]
  • UnitedHealthcare [Columbia University Employee Plan, Compass (Exchange), EPO, Essential Plan, HMO, Medicaid (Community Plan), Medicare Managed Care, POS, PPO]
  • VNSNY CHOICE [Medicare Managed Care, SelectHealth]
  • WellCare [Medicaid Managed Care, Medicare Managed Care]

This provider accepts new patients

Appointment Phone Number: (212) 305-5098

Patents

6/11 Invention entitled: "Use of Adjuvant Focused Radiation Including Stereotactic Radiosurgery for Augmenting Immune Based Therapies Against Neoplasms" Filing Case number: C11601

5/08 Invention entitled: "Manipulation of the Transcription Factor Helios to Enhance or Down-modulate Regulatory T Cell Function" Filing Case number: C10323

9/07 Invention entitled: "Treatment of Th17-mediated Autoimmune Diseases via Inhibition of STAT3" Filing Case number: C10174

3/07 Invention entitled: "Formulation of Toll-like Receptor Ligand with Whole Cell Tumor Vaccine to Enhance Anti-tumor Responses" Filing Case number: C05152

9/06 Invention entitled: "Combinatorial Therapy of Cancer and Infectious Diseases With Vaccine Plus Anti-B7-H1 Antibodies" Filing Case number: C05058

2/06 Invention entitled: "Inducing and Inhibiting T Cell Tolerance with A2a Receptor Agonists and Antagonists" Filing Case number:: C04897

9/04 Invention entitled: "Manipulation of Regulatory T Cell and DC Function by Targeting Neuritin Gene Using Antibodies, Agonists and Antagonists" Filing Case number: C04522

6/03 Invention entitled: "Manipulation of Regulatory T Cells Using LAG-3 Antibodies, Genes, Agonists and Antagonists" Filing Case number: C04255

Committees / Societies / Memberships

2010-present Member, American Association of Immunology (AAI)

2001-present Member, American Association for Cancer Research (AACR)

2000-present Member, American Society of Clinical Oncology (ASCO)

1997-1999 Member, American College of Physicians

Honors & Awards

  • 2015 Resident's Teaching Award, The Brady Urological Institute at Johns Hopkins
  • 2013 Director's Teaching Award in Laboratory-Based Cancer Research; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
  • 2011 Society for Immunotherapy for Cancer- Volunteer Recognition Award
  • 2010 Prostate Cancer Foundation - Creativity Award
  • 2006 V Foundation - Scholar Award
  • 2006 Director's Teaching Award in Clinical Science; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
  • 2004 Damon Runyon - Lilly Clinical Investigator Award
  • 2001 Aventis Fellow - Johns Hopkins Department of Oncology
  • 1997 American College of Physicians Student Abstract Competition(Clinical Vignette Award)
  • 1997 Edward Stoiber Scholar Award for Outstanding Scholarship during All Four Medical School Years
  • 1996 Election to Alpha Omega Alpha (AOA) - Medical Honor Society
  • 1994 E.E. Osgood Award For Highest Ranked Abstract by a Student. Western Society for Clinical Research
  • 1993, 1994 Award For Outstanding Research; University of Colorado Student Research Forum
  • 1993 Viola Vestal Coulter Foundation Scholarship for Graduate Research
  • 1984, 1985 Deans List, Rutgers University College of Engineering
  • 1984 Eta Kappa Nu - Electrical Engineering Honor Society

NIH Grants

  • PHASE 1/2A FIRST-IN-HUMAN STUDY OF BMS-986218 MONOCLONAL ANTIBODY ALONE AND IN COMBINATION WITH NIVOLUMAB IN ADVANCED SOLID TUMORS (P&S Industry Clinical Trial)

    Apr 29 2017 - Apr 29 2022

    A PHASE III, MULTICENTER STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) W/ ENZALUTAMIDE VS ENZALUTAMIDE IN PTS W/ METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AFTER FAILURE OF ANDROGEN SYNTHESIS INHIBITOR / INELIGIBILITY FOR/ REFUSAL OF TAXANE REGIMEN (P&S Industry Clinical Trial)

    Mar 24 2017 - Mar 24 2022

    CANCER CENTER SUPPORT GRANT (Federal Gov)

    Jul 1 2014 - Jun 30 2019

    ENHANCING PROSTATE CANCER IMMUNOTHERAPY THROUGH EPIGENETIC REPROGRAMMING FOR OPTIMAL ACTIVATION OF SPECIFIC EFFECTOR T-CELLS (ERASE-PCA TEAM PROPOSAL) (Private)

    Dec 14 2014 - Dec 23 2017

    IMMUNE-STIMULATING COMBINATORIAL THERAPY FOR PROSTATE CANCER (Federal Gov)

    Nov 1 2016 - Sep 29 2017

    CDK5- A NOVEL ROLE IN PROSTATE CANCER IMMUNOTHERAPY (Federal Gov)

    Oct 1 2016 - Sep 29 2017